Why Tirzepatide Got So Hard to Find

Tirzepatide went from hard to get at the pharmacy to hard to find anywhere else. If you’ve watched sellers disappear or products get renamed, here’s what’s behind it.

What tirzepatide is

Tirzepatide is a dual GIP and GLP-1 receptor agonist made by Eli Lilly. It’s FDA-approved and sold by prescription as Mounjaro for type 2 diabetes and Zepbound for weight management.

The shortage ended

During the tirzepatide shortage, pharmacies could legally compound copies. On December 19, 2024, the FDA confirmed the shortage was resolved for every strength of Mounjaro and Zepbound, and gave compounders grace periods that ran out in early 2025. Mass-produced copies lost their legal footing.

Lilly takes it to court

Lilly has sued compounding pharmacies and telehealth companies it says sold mass-produced copies dressed up as “personalized” medicine, and has gone after what it calls deceptive tirzepatide marketing. In August 2026 it went further, suing businesses over sales of its experimental drug retatrutide, including several “research use only” peptide sellers, and asking payment processors, card companies, platforms and shippers to help cut the trade off.

The FDA’s GLP-1 crackdown

The FDA’s actions against compounded GLP-1 drugs cover tirzepatide too: more than 55 warning letters to online sellers in September 2025, and in February 2026 a plan to restrict the GLP-1 ingredients used in non-approved compounded products.

What regulators are actually targeting

The FDA’s recent warning letters to online peptide sellers, including a round on August 24, 2026, focused on websites marketing compounds for people: dosing charts, injection guides, weight-loss and before-and-after claims. That’s the line that matters. A research supplier sells to researchers, publishes a batch-specific Certificate of Analysis for every lot, and gives no dosing or human-use advice. Sellers that blur that line are the ones disappearing.

The payment squeeze

Payment access is the weak point for anyone selling peptides online. Card processors treat the whole category as high risk: Stripe lists peptides as a restricted business, and most processors simply refuse them. When drug makers and regulators turn up the pressure, processors and platforms are usually the first to act, and sellers that lose payment access tend to disappear within weeks.

That’s why so many listings vanish, change names or move to crypto-only and payment-app checkouts.

What it means if you’re looking

• Expect fewer, less stable sources. Sellers come and go, rename products or switch to payment methods with fewer protections.
• Counterfeit risk rises when supply shrinks. An independent, batch-specific Certificate of Analysis (identity by mass spectrometry, purity by HPLC) matters more than ever. A COA you can’t match to the batch you received isn’t proof of anything.
• Tirzepatide is a prescription medicine. Anyone interested in it as a treatment should talk to a licensed medical provider about the prescription options that exist today.

Sources

• Healio: FDA confirms end of tirzepatide shortage (Dec 20, 2024)
• Foley: FDA re-confirms removing tirzepatide from the shortage list
• Holland & Knight: Eli Lilly strikes back against pharmacy compounders and telehealth platforms (2025)
• Pharmaceutical Technology: Lilly sues Mochi Health and others over tirzepatide marketing
• CNBC: Lilly sues six companies over illegal sales of an experimental obesity drug (Aug 12, 2026)
• Spencer Fane: FDA warning letters to GLP-1 compounders
• FDA: Warning letters (public database)

For the bigger picture on payments, see why payment processors avoid research peptides.

This article summarizes public reporting and regulatory actions. It is general information, not legal or medical advice, and nothing here is dosing or human-use guidance.